Co-Authors
This is a "connection" page, showing publications co-authored by ELSA ARRIBAS and ROSALIND PITPITAN CANDELARIA.
Connection Strength
1.176
-
Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound Med Biol. 2022 06; 48(6):1010-1018.
Score: 0.207
-
Prospective Comparison of Synthesized Mammography with DBT and Full-Field Digital Mammography with DBT Uncovers Recall Disagreements That may Impact Cancer Detection. Acad Radiol. 2022 07; 29(7):1039-1045.
Score: 0.200
-
Mimickers of breast malignancy: imaging findings, pathologic concordance and clinical management. Insights Imaging. 2021 Apr 20; 12(1):53.
Score: 0.195
-
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170.
Score: 0.184
-
Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
Score: 0.168
-
Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2021 07; 54(1):251-260.
Score: 0.048
-
Male Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol. 2020 Dec; 42(12):981-985.
Score: 0.047
-
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
Score: 0.047
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
Score: 0.040
-
Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul; 25(7):1953-1960.
Score: 0.040